Top 10 Contract Development and Manufacturing Organizations 2026
Alex Philippidis analyzes the top CDMOs this year, noting a bright future as biopharma is expected to increase their reliance on CDMOs in coming years despite rising costs for their services. Which companies made the top 10 list? Check out the list to find out.
10 CDMO Up & Comers 2026
The companies listed here, in the “CDMO Up & Comers List” are noted for making headlines with facility openings, major contracts, and other significant actions, though not yet large enough to crack the A-List Top 10 CDMOs.
Next 10 U.S. Biopharma Clusters
For the first time, GEN‘s Alex Philippidis examines the top regions and top states just below the 10 largest regions for life sciences activity, as the field looks beyond the East and West Coasts for growth.
GEN Digital Edition
Access the latest issue of GEN and browse the archive of back issues when you subscribe to our digital edition.
Is Targeted Protein Degradation the “Break” Neurology Needs?
In this GEN webinar, our expert speaker Angela M. Cacace, PhD, will discuss the increasing rationale for targeting key drivers of neurological disease with protein degraders and how this approach may enable deeper, more precise modulation of disease biology.
Angela M. Cacace, PhD
Chief Scientific Officer
Arvinas
Podcast
Touching Base
Touching Base is the dynamic podcast series from the editors of GEN. Each episode features a rotating case of senior editors—including John Sterling, Kevin Davies, Julianna LeMieux, Alex Phillippidis, Uduak Thomas, Corinna Singleman, and Fay Lin—who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what’s now and next. Start listening today!
Stay up to date with the lasted episodes of Touching Base by subscribing to the GEN Podcast Newsletter
StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit
Basecamp Research Raise $140M Series C Financing Toward Advancing AI-Designed Drugs
